Wire · operational-macro
C2N Diagnostics CEO Honored After FDA Clears PrecivityAD2 Alzheimer's Test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
The FDA has cleared the PrecivityAD2 blood test by C2N Diagnostics as the first Alzheimer's disease test for adults with cognitive symptoms as young as 40. This clearance follows extensive use of C2N's biomarker assays in clinical research and collaborations with major diagnostic institutions.
This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it between 11 Sep 2026 and 21 Sep 2026.
◆ ◆ The Wire takeaway
You now have a market cleared for early Alzheimer's detection in adults from 40 years old, shifting patient referral patterns and clinical trial enrolment. This FDA clearance opens a commercial door for you to partner with diagnostic labs and accelerate adoption of blood-based neurodegenerative disease testing.
◆ Coverage
2 sources · first reported 11 Sep 2026 · latest 21 Sep 2026
◆ Related on Wire
◆ Topics